Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide and is highly correlated with hepatitis virus infection. Our previous report shows that a DEAD box RNA helicase, DDX3, is targeted and regulated by hepatitis C virus (HCV) core protein, which implicates the involvement of DDX3 in HCV-related HCC development. In this study, the potential role of DDX3 in hepatocarcinogenesis is investigated by examining its expression in surgically excised human HCC specimens. Here we report the differential deregulation of DDX3 expression in hepatitis virus-associated HCC. A significant downregulation of DDX3 expression is found in HCCs from hepatitis B virus (HBV)-positive patients, but not from HCV-positive ones, compared to the corresponding nontumor tissues. The expression of DDX3 is differentially regulated by the gender and, moreover, there is a tendency that the downregulation of DDX3 expression in HCCs is more frequent in males than in females. Genetic knockdown of DDX3 with small interfering RNAs (siRNA) in a nontransformed mouse fibroblast cell line, NIH-3T3, results in a premature entry to S phase and an enhancement of cell growth. This enhanced cell cycle progression is linked to the upregulation of cyclin D1 and the downregulation of p21 WAF1 in the DDX3 knockdown cells. In addition, constitutive reduction of DDX3 expression increases the resistance of NIH-3T3 cells to serum depletion-induced apoptosis and enhances the ras-induced anchorage-independent growth, indicating the involvement of DDX3 in cell growth control. These findings together with the previous study suggest that the deregulation of DDX3, a DEAD box RNA helicase with cell growth-regulatory functions, is involved in HBV-and HCV-associated pathogenesis.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent malignancy in the world, the third commonest cause of death from cancer worldwide (Parkin et al., 2001a, b) , and the leading cause of cancer death for males in Taiwan (Chen et al., 2002) . HCC is a major health problem in South-East Africa and East Asia (Parkin et al., 2001a) and its occurrence in the Western world has also risen in the last decade, including the United States (El-Serag et al., 2003; El-Serag, 2004) and Europe (Taylor-Robinson et al., 1997) . HCC is two to five times more prevalent in men than in women (Ahn and Flamm, 2004) . The major risk factors for HCC are persistent infection with hepatitis B virus (HBV) (Bre´chot, 2004) and hepatitis C virus (HCV) (Saito et al., 1990; Liang and Heller, 2004) , food contamination with aflatoxin B1, and alcohol abuse (Yu and Yuan, 2004) . HCC development is a multistep process and a consequence of accumulation of genetic abnormalities, which facilitate cell transformation (Hanahan and Weinberg, 2000) . Although the molecular mechanism of hepatocarcinogenesis remains unclear, the genetic lesions in oncogenes, such as ras (Ogata et al., 1991) , c-myc (Kawate et al., 1999) , and tumor suppressors, such as p53 (Nishida et al., 1993; Tanaka et al., 1993; Rashid et al., 1999) and Rb (Murakami et al., 1991; Buendia, 2000; Suriawinata and Xu, 2004) , have been identified in HCC. Moreover, accumulated evidence shows that over 20 cellular genes are up-or downregulated in HCC. They include ras, and c-myc (Zhang et al., 1990) , c-fos, and c-jun (Yuen et al., 2001) , TGF-a (Zhang et al., 2004) , TGF-b1, TGF-b receptor I and II (Paik et al., 2003) , Smad 4 (Torbenson et al., 2002) , c-met (Ueki et al., 1997) , u-PA, t-PA, and uPAR (De Petro et al., 1998) , E-cadherin (Wei et al., 2002) , MDM2 (Endo et al., 2000) , p53 (Kobayashi et al., 2002) , PCNA, and p21
Cip1/WAF1 (Qin et al., 1998) , p27
Kip1 (Tannapfel et al., 2000) , p16 INK4 , cyclin D1, and cyclin E (Jung et al., 2001) , pRb2/p130 (Huynh, 2004) , SAP-1 (Nagano et al., 2003) , PIN1 (Pang et al., 2004) , LFIRE-1/HFREP-1 (Yan et al., 2004) , MXR-7 (Hsu et al., 1997) , and MAGE (Kobayashi et al., 2000) . Many of them are involved in cell cycle checkpoint control; thus, the deregulation of these genes is likely to contribute to the tumor progression.
The human DDX3, also named as CAP-Rf, DDX3X, and DBX, is located at chromosome Xp11.3-p11.23, which escapes X-inactivation in the female (Lahn and Page, 1997; Park et al., 1998; You et al., 1999) , and has two processed pseudogenes on chromosome 4 and X . DDX3 has a functional homolog, DBY, on the Y chromosome (Lahn and Page, 1997) , which has a 91.7% sequence identity to DDX3 at the protein level. DDX3 gene is expressed ubiquitously, and transcribes a mRNA of 5.3 kb, which encodes a protein of 661 amino acids (You et al., 1999) or 662 amino acids (Mamiya and Worman, 1999; Owsianka and Patel, 1999) . DDX3 contains all the nine highly conserved motifs of a DEAD-box family RNA helicase (Rocak and Linder, 2004) , including the Asp-Glu-Ala-Asp motif, which gives the protein family its name and distinguishes it from other related RNA helicase protein families (Linder et al., 1989; Lu¨king et al., 1998) . This family of RNA helicases plays a fundamental role in RNA metabolism, including transcription, pre-mRNA splicing, ribosome biogenesis, RNA transport, translation initiation, organelle gene expression, and RNA decay (Rocak and Linder, 2004) . Although the DEAD box proteins share similar biological function, covering many aspects of RNA metabolism, they also play unique roles in other cellular processes, such as growth regulation and tumor development. For example, the p68 DEAD box RNA helicase has been shown to be involved in cell proliferation (Stevenson et al., 1998; Kahlina et al., 2004) , and overexpression of several DEAD box proteins p68, rck/p54, and DDX1 has been found in tumors (Godbout et al., 1998; Nakagawa et al., 1999; Causevic et al., 2001) . These are indicative of a relationship between DEAD box proteins and abnormal or proliferative disease. Being a new member of the DEAD-box RNA helicase family, DDX3 has been suggested to be involved in RNA splicing (Zhou et al., 2002) , RNA transport (Yedavalli et al., 2004) , and translation initiation (Mamiya and Worman, 1999) . Previous reports, including ours, show that DDX3 interacts with the HCV core protein, while the function of DDX3 is also regulated by this viral protein (Mamiya and Worman, 1999; Owsianka and Patel, 1999; You et al., 1999) . Although the upregulation of DDX3 mRNA in HCC has been reported (Huang et al., 2004) , the role of DDX3 in hepatocellular carcinogenesis is yet to be determined.
In this study, we examined whether DDX3 is associated with HCC pathogenesis and how DDX3 targets cell growth regulation. Specifically, the expression of DDX3 in HCC patients with HBV or HCV infection was analysed by immunohistochemistry, Western blot analysis, and quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR). These analyses revealed a higher frequency of DDX3 downregulation in the male gender of HCC patients and in patients with HBV infection. In addition, proliferative and antiapoptotic phenomena were found in DDX3 downregulated NIH-3T3 cells using a small interfering RNA (siRNA) approach. Our results suggested that downregulation of DDX3 expression may contribute to HBV-associated hepatocarcinogenesis. This together with the previous finding that DDX3 is also a cellular target of HCV core protein imply that the deregulation of DDX3, a cell growth regulator with plethoric functions, is likely associated with HBV-and HCVrelated pathogenesis.
Results

Deregulation of DDX3 expression in HCC specimens
To investigate the possible correlation of DDX3 expression level with liver tumor formation, we analysed the expression profiles of DDX3 in liver tumor tissues and the adjacent nontumor liver parts by immunohistochemistry staining (IHC staining) and Western blot analysis (see Materials and methods). Immunohistochemical study was performed using DDX3 polyclonal antibody. The intensity of DDX3 immunostaining in tumor and nontumor tissues was measured and expressed as a labeling score (see Materials and methods). In these 41 paraffin-embedded HCC specimens, DDX3 expression decreased in 24 HCC specimens (59%), while its expression remained unchanged or enhanced in nine (22%) or eight (19%) HCC specimens, respectively. Figure 1a shows the IHC-staining profiles of four HCC specimens, and that these histopathological results revealed a decrease of DDX3 expression.
To further confirm the deregulation of DDX3 expression in HCCs obtained by semiquantitative IHC-staining, we carried out Western blot analysis on another 60 frozen tumor and nontumor paired HCC specimens using the DDX3 polyclonal antibody. Actin and U1 snRNP 70 were also probed to serve as a control for the amount of protein loading. Figure 1b shows 17 examples of DDX3 expression profile in these HCC specimens. Analysis of these 60 paired HCC specimens revealed that the DDX3 expression decreased in 30 HCC specimens (50%, tumor:nontumor ratio o 0.5), of which 18 (30%) had HBV infection, eight (13%) had HCV infection, and four (7%) were without HBV and HCV infection. Consistent with the histopathological results, Western blot analysis also revealed a decrease of DDX3 expression in about 50% of the HCC specimens. Moreover, it appears that the expression status of DDX3 in HCC specimens with or without hepatitis virus (HBV or HCV) infection could be classified into three groups, that is, reduced, unchanged, and enhanced, as compared to the corresponding nontumor liver tissues.
Next, to assess whether the mRNA expression profile of DDX3 in HCCs is consistent with its protein expression level, we analysed the mRNA levels of DDX3 in 17 paired tumor and nontumor liver tissues that have been classified into three different groups (reduced, unchanged, and enhanced) based on Western blot data. As shown in Figure 2 , when using quantitative RT-PCR to determine the relative DDX3 mRNA expression level (see Materials and methods), at least two-to four-fold reduction of DDX3 mRNA was found in the HCC specimens with decreased DDX3 protein expression. This suggests a correlation of the DDX3 protein reduction to its mRNA downregulation. However, for the other two groups of HCC specimens (enhanced or unchanged DDX3 protein level), their relative DDX3 mRNA levels displayed essentially at the range of control (less than two-fold difference) (Figure 2) . When taking these into consideration, the DDX3 expression profile in HCC specimens can be simply classified into two categories, reduced and not reduced, for statistical analysis.
Correlation of DDX3 expression with clinicopathological parameters To determine which clinical parameters affect the DDX3 expression level, its expression profile obtained by Western blot analysis (60 HCC cases) was analysed based on six clinical categorical variables (gender, hepatitis virus infection, tumor size, recurrence, survival, and age) using w 2 analysis. Table 1 summarized the w 2 analysed data and revealed that the expression level of DDX3 in patients with HCC had a significant correlation with gender (P ¼ 0.037) and hepatitis virus infection (P ¼ 0.006), but was not correlated with tumor size, recurrence, survival, and age. Specifically, our results indicated a higher prevalence of DDX3 reduction in male (58%) than in female (27%) HCC patients. In addition, our results also showed a lower prevalence of DDX3 reduction in HCV-positive specimens (30%) and a higher prevalence of DDX3 reduction in HBV-positive ones (67%). In conclusion, our clinical data revealed that the downregulation of DDX3 expression was highly Deregulation of DDX3 in hepatocellular carcinoma P-C Chang et al prevalent in HBV-positive HCC specimens and in the male gender of HCC patients.
Differential expression of DDX3 in male and female genders of liver tissues The higher frequency of DDX3 downregulation in the male gender of HCC patients is rather interesting, especially when considering that HCC is two to five times more prevalent in males than in females (Ahn and Flamm, 2004) . Since DDX3 is located at chromosome X and escapes X-inactivation in the female (Lahn and Page, 1997) , the expression levels of DDX3 in male and female genders might be different. To test this possibility, we compared the expression level of DDX3 in 16 nontumor liver specimens of male and female genders using Western blot analysis. As shown in Figure 3 , the expression level of DDX3 in female specimens is about 1.5-3-fold higher than that in male specimens when using actin or U1 snRNP 70 as the internal control. A similar conclusion was obtained when examining the mRNA expression level of DDX3 in different gender by RT-PCR (see Materials and methods) (data not shown).
In conclusion, our results support the notion that DDX3 expression escapes the X-inactivation. This differential expression of DDX3 in different genders may presumably affect the outcome of its downregulation in hepatocarcinogenesis.
Establishment of small interfering RNAs (siRNA) targeting DDX3 knockdown cell lines
To identify the cellular function altered by DDX3 downregulation, we established DDX3 knockdown stable clones in a nontransformed mouse fibroblast NIH-3T3 cell line. To this end, we utilized a recently developed post-transcriptional gene knockdown technique, small interfering RNAs (siRNA), to suppress the DDX3 expression in a sequence-specific manner. Since the gene-silencing effect of siRNA may be influenced by the secondary structure of the targeting mRNA, we designed four siRNA target sites (see Materials and methods) along the coding region of DDX3 (see Figure 4a ) according to the general siRNA design guide.
To avoid targeting and silencing other DEAD box family proteins simultaneously, the four selected siRNA target sites are not made a part of the DEAD box family consensus sequence (see Figure 4a , designated as domain Q and I-VI in DDX3 polypeptide chain). In addition, the four selected target sites were blasted against the genome database of the National (Figure 5a ), thereby allowing the establishment of two DDX3 downregulated NIH-3T3 cell lines, siDDX3-433-25 and siDDX3-433-31 ( Figure 5b ). This is consistent with the blast result of Figure 3 The expression level of DDX3 in liver tissues is higher in females than in males. The protein expression levels of DDX3 in male and female genders were examined by Western blot analysis of whole liver tissue extracts prepared from nontumor tissues of eight female HCC specimens and eight male HCC specimens, as indicated. The expression levels of actin and U1 snRNP 70 were also analyzed to show the amount of protein loading.
human siRNAs to the equivalent region in mouse DDX3X, the homolog of human DDX3, since the one nucleotide mismatch at the border of siDDX3-433/452 had a negligible effect in gene silencing (Figure 4b ).
Knockdown of DDX3 expression in NIH-3T3 cells accelerates the cell proliferation
The proliferative effect of DDX3 downregulation was examined by 3 0 -(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, inner salt) assay (see Materials and methods). Figure 5c showed the accelerated proliferation rate of DDX3 knockdown NIH-3T3 cell lines, siDDX3-433-25 and siDDX3-433-31, as compared to the control clone. To further understand the mechanism of the increased growth rate, fluorescence-activated cell sorting (FACS) analysis was used to analyse the cell cycle alteration in the control and DDX3 knockdown NIH-3T3 cell lines (see Materials and methods). These cell lines were synchronized by serum starvation for 24 h and relieved by adding bovine calf serum (BCS) for 10-24 h. As shown in Figure 6a and b, approximately 50% (51-57%) of the cells of the siDDX3-433-25 and siDDX3-433-31 clones entered S phase at 12 h, reaching a maximum (82-85%) at 14 h and exiting the S phase at 16 h, while only 21% of the control clone had entered S phase at 12 h and this reached a maximum (96%) at 16 h. These results indicate that accelerated cell growth may have resulted from an earlier start of DNA synthesis in the DDX3 knockdown NIH-3T3 cell line.
To further elaborate the underlying mechanism by which the loss of DDX3 promotes S-phase entry, the expression patterns of the S-phase-related cell cycle regulators in synchronized control and DDX3 knockdown cells (siDDX3-433-31 clone) following serum stimulation for 0-, 1-, 2-, 4-, 10-, and 24-h periods were determined using Western blot analysis (see Materials and methods). As shown in Figure 7 , in DDX3 knockdown cells, cyclin D1 was expressed at a higher level at time points 1-2 h after serum stimulation, while p21 WAF1 was constitutively expressed at a lower level at all time points (0-24 h) examined compared to the control. In contrast, the expression of the other cell cycle regulators cdk2, cdk4, cyclin A, cyclin E, and p27 was not affected by downregulation of DDX3. Since cyclin D1 is a key regulator in early to mid-G1 phase, the higher expression level of cyclin D1 at early time points in the DDX3 knockdown cells may contribute to its premature entry to the S phase (see Figure 6 ). In addition, the lower expression level of the cdk inhibitor p21 WAF1 throughout the cell cycle may help to explain the accelerated cell growth found in DDX3 knockdown cells. In summary, genetic knockdown of DDX3 in NIH-3T3 cell line results in premature entry into the S phase of the cell cycle and proliferation at an accelerated rate. This dysregulation in cell cycle control caused by the reduction in DDX3 is linked to the upregulation of cyclin D1 and the downregulation of p21 WAF1 . Knockdown of DDX3 expression in NIH-3T3 cells increases the cell resistance to serum depletion-induced apoptosis Since nontransformed NIH-3T3 fibroblasts are highly sensitive to serum depletion, the sensitivity of DDX3 knockdown NIH-3T3 cell line to serum depletion was determined. These cell lines were subjected to serum starvation for 3 days and the viable cells during the serum starvation period were analysed by MTS assay (see Materials and methods). Figure 8a showed that the DDX3 knockdown NIH-3T3 clones, siDDX3-433-25 and -31, were more resistant to serum depletion-induced cell death compared to the control. To further confirm the resistance to serum depletion-induced cell death in DDX3 knockdown NIH-3T3 cells, the apoptotic cells of these three cell lines after serum depletion were also analysed by the TUNEL assay (see Materials and methods). Consistent with the results of MTS assay, these two DDX3 knockdown clones yielded 10-20% less apoptotic cells than the control after serum starvation for 2-3 days (Figure 8b ). These results indicate that the downregulation of DDX3 in NIH-3T3 cell line increases cell resistance to serum starvation-induced apoptosis.
Knockdown of DDX3 expression in NIH-3T3 cells enhances the oncogenic v-ras-induced anchorage-independent cell growth To determine whether DDX3 deficiency rendered NIH-3T3 fibroblasts more susceptible to transformation, the transformation property of DDX3 knockdown cells was characterized by soft agar assay and nude mice experiments (see Materials and methods). Both control and DDX3 knockdown NIH-3T3 cells (siDDX3-433-25 and siDDX3-433-31) failed to produce foci in soft agar assay ( Figure 9 ). Consistent with the in vitro soft agar assay, no tumor formation occurred after injection of either control or DDX3 knockdown NIH-3T3 cells into nude mice (data not shown). These results suggest that knockdown of DDX3 expression does not render NIH-3T3 cells more susceptible to transformation. To further assess whether knockdown of DDX3 expression in cooperation with oncogene rendered NIH-3T3 fibroblasts more susceptible to transformation, the control and DDX3 knockdown NIH-3T3 cells were transfected with plasmid expressing c-myc or v-ras and the foci formed in soft agar were measured in 2 weeks. While transfection of c-myc expression plasmid failed to produce foci in the control or the DDX3 knockdown NIH-3T3 cells, DDX3 knockdown cells expressing v-ras generated foci larger than that of the control (Figure 9 ). These results indicate that knockdown of DDX3 expression in cooperation with v-ras expression renders NIH-3T3 cells more susceptible to anchorage-independent growth.
Discussion
In this study, we generated a DDX3 knockdown cell line to address how DDX3 exerts its cellular functions. We showed that the suppression of endogenous DDX3 expression promoted cell cycle transition from G0/G1 to S phase, leading to enhanced cell proliferation (Figures 5  and 6 ). In addition, we demonstrated that knockdown of DDX3 inhibited serum depletion-induced apoptosis and enhanced the v-ras-induced anchorage-independent growth (Figures 8 and 9 ). Most importantly, we identified a frequent downregulation of DDX3 in HBV-positive HCC specimens, compared to adjacent nontumor parts (see Figure 1 and Table 1 ). These findings suggest that the downregulation of DDX3 promotes cell proliferation and antiapoptosis, which leads to a defect in cell growth control and presumably contributes, in part, to liver tumor formation. Deregulation of DDX3 in hepatocellular carcinoma P-C Chang et al DDX3 is a new member of the DEAD box family RNA helicase. To date, increasing evidence shows that these DEAD family proteins are also involved in cell proliferation regulation and tumorigenesis. For example, a prototypic DEAD box RNA helicase, p68, was recently found to be induced during serum stimulation in NIH-3T3 fibroblasts (Stevenson et al., 1998) and keratinocytes (Kahlina et al., 2004) , and is overexpressed in colorectal tumors (Causevic et al., 2001) . This is rather different from DDX3 because this protein's expression is downregulated in liver tumors (see Figure 1 and Table 1 ) and a reduction in DDX3 expression promotes cell proliferation in NIH-3T3 cells ( Figure 5 ). In the present study, we also found out that the reduction in DDX3 upregulates cyclin D1 and downregulates p21 WAF1 (Figure 7 ). This implies that DDX3 may regulate the cell cycle progression through more than one regulator. Notably, numerous reports on different human cancers also show alterations in the expressions of p21 WAF1 and cyclin D1. For example, the expression of p21 WAF1 has been found to increase in cutaneous squamous cell carcinoma (Tron et al., 1996) and non-small-cell lung carcinoma (Marchetti et al., 1996) , but decrease in gastric carcinoma (Xie et al., 2004) , colorectal carcinoma (Matsushita et al., 1996) , and ovarian carcinoma (Lukas et al., 1997) ; notably, in HCC, both increases and decreases of p21 WAF1 expression have been observed (Furutani et al., 1997; Hui et al., 1997; Qin et al., 1998; Shi et al., 2000; Fukushima et al., 2001) . Moreover, the overexpression of cyclin D1 has been identified in a wide variety of human malignancies (Fu et al., 2004) including HCC (Sato et al., 1999; Joo et al., 2001; Masaki et al., 2003) , and, most interestingly, this overexpression is sufficient to initiate HCC development in mice (Deane et al., 2001) . Therefore, the deregulation of p21 WAF1 and cyclin D1 expression in DDX3 knockdown cells may help explain the potential role of DDX3 loss in carcinogenesis. It should also be noted that, apart from proliferation regulation, DDX3 has a distinct feature in terms of cell death control, which is not found in other DEAD box family members. Although the precise nature of this antiapoptosis process is unclear, our preliminary data show that an inability to activate caspase 6 and 9 in DDX3 knockdown cells is likely to be one of the reasons for this phenotype (data not shown). Therefore, in the absence of DDX3, cells may acquire a selective advantage for uncontrolled proliferation and apoptosis, both of which are typically involved in tumorigenesis.
On the basis of our clinical results, the DDX3 expression was frequently downregulated in the HCC specimens (see Table 1 and Figure 1 ). Whether this loss of DDX3 expression is causally related to HCC development, or merely reflects a wide spectrum of gene expression alteration in HCC, is not clear yet. Gene expression alteration in tumors generally involves several mechanisms, including (i) genetic changes, such as amplification, mutation, deletion, loss of heterozygosity (LOH); (ii) epigenetic changes, such as aberrant methylation and acetylation; (iii) post-transcriptional regulation by microRNA (miRNA); and (iv) posttranslational modification, such as phosphorylation, acetylation, ubiquitination, and sumoylation (AlarconVargas and Ronai, 2002; Albertson et al., 2003; Brooks and Gu, 2003; Macaluso et al., 2003; Shackelford and Pagano, 2004; Gregory and Shiekhattar, 2005) . Although numerous genetic changes have been observed in HCC, these changes have been identified only in a limited number of chromosome arms not including where DDX3 resides on the X chromosome (Buendia, 2000; Tannapfel and Wittekind, 2002; Thorgeirsson and Grisham, 2002) . This suggests that mechanisms other than genetic change are involved in the downregulation of DDX3 in HCC. A previous report shows that the mRNA of DDX3 is upregulated in HCC (Huang et al., 2004) , which contradicts with our data because the downregulation of both mRNA and protein level of DDX3 was observed in at least 50% of the HCC specimens (see Figures 1 and 2 , Table 1 ). The exact reason for this discrepancy is not clear. However, in this study we notice that although the protein level of DDX3 may have more than two-fold increase in certain HCC specimens, their mRNA levels in these HCC specimens display essentially as the control (see Figure 2) . This suggests that post-transcriptional regulation or posttranslational modification may also participate in the deregulation of DDX3 in HCC as reported here. Therefore, further analysis of the expression regulation of DDX3 may provide a potential role of DDX3 as a therapeutic target for human HCC.
An interesting observation made in this study is the high incidence of downregulation of DDX3 in HCCs with HBV infection and the lower extent of downregulation in HCV-positive HCCs (Table 1) . This clinical observation suggests a possible and complicated scenario for hepatitis virus infection and DDX3 deregulation in HCC development. Firstly, in HBV infected patients, HBV may downregulate the expression of DDX3 through regulation of cellular genes expression by its viral products (Bre´chot et al., 2000) , which in Figure 7 Upregulation of cyclin D1 and downregulation of p21 WAF1 during cell cycle entry in DDX3 knockdown cell lines. The whole cell extract was collected from control (Ctrl), and DDX3 knockdown NIH-3T3 clone, siDDX3-433-31 (siDDX3), and these were synchronized by a 24-h serum starvation. Following serum stimulation ( þ BCS) at the indicated time points, they were subjected to Western blot analysis using an antibody specific for G0/G1 to S-phase cell cycle regulators (see Materials and methods). The unsynchronized NIH-3T3 cells were used as a control for Western blot analysis.
combination with other events caused by virus may result in HCC. Notably, since the HBx protein was found to repress gene expression by methylationmediated promoter inactivation (Lee et al., 2005) , the downregulation of DDX3 expression in HBV-positive HCC specimens is presumably caused by the same mechanism. Secondly, since previous reports including ours indicate that DDX3 is one of the cellular targets for the oncogenic core protein of HCV (Mamiya and Worman, 1999; Owsianka and Patel, 1999; You et al., 1999) , it is possible that, in HCV-induced tumorigenesis, the biological function of DDX3 may be diminished by HCV core-mediated inactivation, but not by reduction of its expression. If this is the case, deregulation of DDX3 may serve as one of the risk factors in both HBV-and HCV-related pathogenesis.
It should be noted that a two to five times higher incidence of HCC in males than females has been reported (Chen et al., 2002; Ahn and Flamm, 2004) . Although several environmental risk factors have been correlated with this observation, the detailed mechanism of this predominance of HCC occurrence in the male gender is obscure (Ahn and Flamm, 2004) . It has also been noted that although a number of genes have been identified to be up-or downregulated during hepatocarcinogenesis (see Introduction), the molecular mechanism of the high incidence of HCC development in male gender remains unclear. Notably, the differential expression of DDX3 in different genders, as reported here (see Figure 3) , might affect the outcome of its downregulation in different genders, especially if the deregulation of DDX3 is an important risk factor for HCC. In line with this, the higher prevalence of DDX3 downregulation in the male gender of HCC patients, as has been found in this work (see Table 1 ), may suggest a potential role of DDX3 as a target for the diagnosis of human HCC, especially in the male gender.
Materials and methods
HCC specimens
A total of 101 HCC specimens, including 41 paraffinembedded HCC tissue sections and 60 paired specimens of frozen tumor and nontumor liver tissue, were collected from the Department of Surgery at the Taipei Veterans General Hospital between 1985 and 1988. In the 41 paraffin-embedded HCC tissue sections, 12 sections were associated with HCV infection, 16 sections with HBV infection, five sections with HBV and HCV superinfection, and eight sections were without HBV and HCV infections. Among the 60 specimens of frozen tissues, there were 27 HCV-positive specimens, 27 HBVpositive ones, one HBV and HCV superinfected one, and five HCV-and HBV-negative ones. The association between DDX3 expression and clinical parameters was statistically analysed by the w 2 test and Po0.05 was defined as statistically significant.
Antibodies
For cell cycle analysis, the total cell lysates from serumstimulated control and DDX3 knockdown NIH-3T3 cell lines were analysed by antibodies against cyclin A (Ab-3; Oncogene, Boston, MA, USA), cyclin D1 (2926; Cell Signaling, Beverly, MA, USA), cyclin E (Ab-2; Calbiochem), cdk2 (anticdk2mAb; Transduction Laboratories, Lexington, KY, USA), cdk4 (Ab-2; Oncogene), p21 WAF1 (ab7960; Abcam, Cambridge, UK), p27 (sc-528; Santa Cruz, CA, USA), U1 snRNP 70 (sc-9571, Santa Cruz) and actin (sc-1616, Santa Cruz). To generate a polyclone antibody of DDX3 protein, a fragment containing amino acids 1-226 of the human DDX3 was cloned into pGEX-5X-1 plasmid (Amershsam, Piscataway, NJ, USA) to generate GST-tagged DDX3 protein. The purified GST-DDX3/1-226 protein was used to generate anti-DDX3 polyclone antibody by Custom Antibody Services of Protech Technology Enterprise Co., Ltd. The preimmune serum was collected from rabbits prior to immunization. The specificity of the purified DDX3 antibody was examined and confirmed by immunoblot using hepatoma cell lysates (HuH-7 and HepG2) (data not shown). 
Immunohistochemistry staining (IHC-staining)
The paraffin sections from the HCC specimens were deparaffinized in xylene, rehydrated through graded alcohols (100, 90, 80, 70, 50%) , subjected to antigen retrieval by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min, and the endogenous peroxidase activity was blocked with 3% H 2 O 2 in ddH 2 O for 10 min at room temperature. The slides were blocked with antibody diluent with background-reducing components (DAKO, Carpinteria, CA, USA) and incubated overnight at 41C with the DDX3 polyclonal antibody. The 1:100 dilution of DDX3 antibody was found to be optimal for IHC staining. The immunodetection was visualized using horseradish peroxidase (HRP)-conjugated streptavidin antibody and the color development followed a standard protocol using 3-amino-9-ethylcarbazole (AEC) (DAKO) as the chromogen. Tissue sections were counterstained with hematoxylin. The liver histology and extent of DDX3 protein staining in the tumor and nontumor tissue parts of clinical samples was evaluated by a pathologist in a blind fashion using a four-tier scale to represent negative, weak, intermediate, and strong signals. Reduced DDX3 expression was defined as lower DDX3 labeling index in HCC tissue compared with the adjacent nontumor tissue. The IHC staining was performed in two separate batches with several specimens overlapped in these two batches in order to examine the consistency of the assay system. The results reported by the pathologist were consistent for these repeats in terms of the trend of DDX3 expression. We also stained a section with preimmune rabbit serum (1:100 dilution) and no staining was obtained, indicating the specificity of the DDX3 antibody (data not shown).
Western blot analysis
Total protein from the HCC specimens was extracted by a MagNA Lyser homogenizer (Roche, Penzberg, Germany) in protein extraction buffer (10 mM NaCl, 10 mM KCl, 10 mM EDTA, 10 mM DTT, 0.5% NP-40, and 20 mM Tris-HCl, pH 7.8) containing 1 Â completet protease inhibitor (Roche). The homogenate was centrifuged at 12 000 r.p.m. for 15 min at 41C and the protein concentration was measured using Bradford reagent (Bio-Rad, Hercules, CA, USA). A total of 100 mg of protein/sample was resolved on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane (Hybondt-c extra; Amersham) and detected by enhanced chemiluminescence (ECL; PIERCE, Rockford, IL, USA).
Quantitative real-time RT-PCR Total RNA was isolated from HCC specimens using the Tri reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manual. Before use, total RNA pellet was washed by 70% ethanol and dissolved in DEPC-water. cDNA was synthesized from 2 mg of total RNA using SuperScriptt II reverse transcriptase in a final volume of 20 ml. DDX3 was amplified by using the primer sets 5 0 -CATCGTATTGGTCG TACGG-3 0 (nt 1578-1597) and 5 0 -GCACCGCTACTTTGTC GGTA-3 0 (nt 1823-1803). The porphobilinogen deaminase (PBGD) was used as an internal control for quantification using the primers 5 0 -GCTGCAACGGCGGAA-3 0 (nt 21-36) and 5 0 -CCTGTGGTGGACATAGCAATGATT-3 0 (nt 179-155). PCR was performed in LightCycler system using FastStart DNA master SYBR green I kit as described in the instruction manual. Negative control (no-template) was included in every assay to assess the overall specificity. The relative expression fold was analysed by Real Quant software using PBGD as the housekeeping normalization gene.
siRNA design and construction
To establish the stable cell lines with a reduction in the expression of DDX3 gene, four siRNA target sites were selected according to the general siRNA design guide by RNAi design tools at OligoEngine, the pSuper RNAi design tool (http://www.oligoengine.com). The four DDX3 siRNA target sites were located at nt 135-154, 433-452, 1166-1185 , and 1692-1711 from the start codon (see Figure 4) . The oligonucleotides of 64-basis hairpin derivatives for generating DDX3 siRNA were synthesized and designated as siDDX3-135/154
, and siDDX3-1692/1711 (5 0 -G ATCCCACAAGAAGTGCCGTCTTGGTTCAAGAGACC AAGACGGCACTTCTTGTTTTTTTGGAAA-3 0 ). These oligonucleotides were then annealed and cloned into the pSuper plasmid containing the H1 promoter. The clones containing the DDX3 siRNA oligonucleotides were designated as psiDDX3-135, psiDDX3-433, psiDDX3-1166, and psi DDX3-1692, respectively.
Cell culture and transfection
The Swiss mouse embryo fibroblast NIH-3T3 cell line was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated BCS (Gibco, Carlsbad, CA, USA), MEM nonessential amino acids solution (Gibco), L-glutamine, and penicillin/streptomycin/amphotericin at 371C under 5% CO 2 . To establish the DDX3 knockdown stable NIH-3T3 cell lines, the siRNA containing plasmids, psiDDX3-135, psiDDX3-433, psiDDX3-1166, psiDDX3-1692, or the control plasmid, pSuper, were cotransfected with the pTRE2-Hyg plasmid encoding hygromycin Bresistant gene into NIH-3T3 cells (1 Â 10 5 cells/well of a sixwell plate) by the calcium phosphate transfection method. The transfectants were reseeded and selected using 200 mg/ml of hygromycin B (Calbiochem). After 2 weeks of selection, the hygromycin B-resistant colonies were collected and the reduction of DDX3 expression was confirmed by Western blot analysis. Their respective expression knockdown efficiency is demonstrated by the ratio of DDX3 to actin, as shown by Western blotting. For soft agar assay, NIH-3T3 cells were seeded at 2 Â 10 5 cells/well of six-well plates and transfected with 1 mg plasmid of pZIP-v-H-ras or pMT2T-wt-myc by LipofectAMINE 2000 (Invitrogen, Carlsbad, CA, USA) according to the manual provided by the manufacturer.
Cell growth, cell cycle, and apoptosis analysis For cell growth analysis, cells were seeded in a 96-well plate at a density of 2 Â 10 3 -6 Â 10 3 cells and were analysed every 24 h by an MTS assay kit (Promega, Madison, WI, USA) according to the manual. To analyse the cell cycle progression, the NIH-3T3 cells were harvested at the indicated time points following serum stimulation, fixed in ice-cold 70% ethanol, washed with PBS, permeabilized by 0.1% Triton X-100, and stained by 0.02 mg/ml propidium iodide (PI) containing 0.2 mg/ml of DNase-free RNase for 30 min at 371C. The cells were analysed by a fluorescence-activated cell sorter (FACS) using a BD Biosciences FACSAN apparatus and ModFit LT software. For the apoptosis assay, NIH-3T3 cells were subjected to serum depletion in BCS levels from 10 to 0%. Apoptotic cells were identified by the FragELt DNA Fragmentation Detection Kit (Calbiochem) using BD Biosciences FACSAN apparatus and CellQuest software.
Soft agar and tumorigenecity assays Soft agar assays were performed by seeding NIH-3T3 cells (5 Â 10 4 cells/well) as a single-cell suspension in 0.35% agarose in DMEM containing 10% BCS over a previously gelled layer of 0.7% agarose in the same complete medium in six-well plates. After incubation for 14 days, colonies were stained overnight with p-iodonitroterazolium violet (1 mg/ml; Sigma) at 371C. Colonies larger than 200 mm were counted. All the experiments were performed in triplicates. Tumorigenicity was investigated by the subcutaneous injection of the control and DDX3 knockdown NIH-3T3 cells (1 Â 10 7 cells/0.2 ml PBS) into the back of 6-8-week-old male CD1(ICR)-nude mice. The HeLa cells (7 Â 10 6 cells/0.2 ml PBS) were also injected as a positive control. The mice were examined every 3 days and killed on the 25th day. The nude mice were purchased from the National Laboratory Animal Center in Taiwan and kept under pathogen-free conditions.
